Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | ADIPOR2 | Q86V24 | 1/20 | 0.69 |
| ▸ | ADIPOR1 | Q96A54 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.66 |
| ▸ | FAAH | O00519 | 3/20 | 0.63 |
| ▸ | BCHE | P06276 | 3/20 | 0.63 |
| ▸ | ACHE | P22303 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24514563 | 0.92 | POLB (0.86) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL24514573 | 0.92 | POLB (0.74) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL25569213 | 0.89 | POLB (0.70) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL25568937 | 0.88 | POLB (0.66) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL4031641 | 0.87 | POLB (0.70) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL17950896 | 0.84 | POLB (0.63) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL25568933 | 0.84 | ADIPOR2 (0.73) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL17946047 | 0.84 | POLB (0.91) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL24514564 | 0.83 | ADIPOR2 (0.82) | POLBADIPOR2ADIPOR1USP2MCHR1 | |
| SCHEMBL17945987 | 0.83 | POLB (0.84) | POLBADIPOR2ADIPOR1USP2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234923-A1 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | TRUSTEES OF TUFTS COLLEGE | 2023-07-27 | — | — | US | disclosed |
| US-11655212-B2 | Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes | TRUSTEES OF TUFTS COLLEGE (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655212-B2 | Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes | ADIPOR1, ADIPOR2, GPR119 | POLB 3985/4885ADIPOR2 2/4885ADIPOR1 1/4885 |
| US-20230234923-A1 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | ADIPOR1, ADIPOR2, GPR119 | POLB 3985/4885ADIPOR2 2/4885ADIPOR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.